Alzheimer’s Blood Test Predicts Who Might Benefit Most From Anti-Amyloid Drugs
Plasma phosphorylated tau 217 (p-tau217) outperformed p-tau181, p-tau231, and other blood-based biomarkers to identify which patients might benefit most from anti-amyloid Alzheimer’s drugs, a cohort study showed. Plasma p-tau217 helped rule out two groups who would not likely benefit: those who were amyloid-negative, and those who were amyloid-positive but had a high tau burden, reported […]
Sparsentan Bests Irbesartan for Preserving Kidney Function in IgA Nephropathy
PHILADELPHIA — Sparsentan (Filspari) outperformed irbesartan in patients with IgA nephropathy over the 2-year phase III PROTECT trial. Over a 110-week treatment period, those on sparsentan had an average 42.8% (95% CI -49.8 to -35.0) reduction in urine protein-to-creatinine ratio compared with a 4.4% (95% CI −15.8 to 8.7%) reduction with irbesartan (geometric least-squares mean […]
Once-Weekly Insulin Icodec Bests Daily Insulin Options for Type 2 Diabetes
SAN DIEGO — Investigational once-weekly insulin icodec outperformed once-daily insulin glargine U100 when it came to glycemic control in type 2 diabetes, the phase IIIa ONWARDS 1 trial found. Over the course of 52 weeks, people with type 2 diabetes saw a greater average reduction in HbA1c with icodec compared with glargine U100 (estimated between-group […]